Haukeland University hospital

Bergen N5021

15 studies enrolling now · 47 studies all time

What they study most

Achondroplasia, Acute Myeloid Leukemia, Advanced Melanoma, Advanced Solid Tumors, Agglutinin Disease, Cold, Anaesthesia, Anal Carcinoma, B-Cell Malignancies, Basal Cell Carcinoma (Unresectable or Metastatic), Blood Transfusion, Bone Marrow Aplasia, Cancer-associated Cachexia

Studies at this site

Visugromab in Cachexia International Trial — Recruiting now
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer — Recruiting now
A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia — Recruiting now
A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus — Recruiting now
Prospective Clinical Assessment Study in Children With Hypochondroplasia — Recruiting now
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer — Recruiting now
A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia — Recruiting now
FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3 — Recruiting now
Observational Study of Adults and Adolescents With Erythropoietic Protoporphyria (EPP) and X-linked Porphyria (XLP) — Recruiting now
A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms — Recruiting now
IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) — Recruiting now
Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) — Recruiting now
A Fabry Disease Gene Therapy Study — Stopped early
A Registry for Participants With Chronic Hypoparathyroidism — Completed
A Study to Evaluate the Long-term Safety and Tolerability of Lucerastat in Adult Subjects With Fabry Disease — Running, not enrolling
Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465) — Running, not enrolling
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation — Running, not enrolling
Open-Label, Long-Term, Extension Study of Infigratinib in Children With Hypochondroplasia — Enrolling by invitation
Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN) — Running, not enrolling
A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis — Running, not enrolling
Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix — Completed
Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria or X-Linked Protoporphyria — Completed
Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer — Running, not enrolling
Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2). — Completed
Extension Study of Infigratinib in Children With Achondroplasia (ACH) — Enrolling by invitation
A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With Cold Agglutinin Disease (CAD) — Completed
To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313) — Stopped early
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors — Stopped early
A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies — Stopped early
To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304) — Stopped early
Open-Label Surufatinib in European Patients With NET — Stopped early
An Efficacy and Safety Study of 24 Week Treatment With Mavodelpar (REN001) in Primary Mitochondrial Myopathy Patients — Completed
A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA — Completed
Thrombosomes® in Bleeding Thrombocytopenic Patients — Completed
A Study to Assess the Efficacy and Safety of BIVV009 (Sutimlimab) in Participants With Primary Cold Agglutinin Disease Without A Recent History of Blood Transfusion — Completed
A Study to Assess the Efficacy and Safety of BIVV009 (Sutimlimab) in Participants With Primary Cold Agglutinin Disease Who Have a Recent History of Blood Transfusion (Cardinal Study) — Completed
A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia — Enrolling by invitation
Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC — Stopped early
Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcomas — Status unconfirmed
A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) — Completed
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer — Completed
Local Assessment of Ventilatory Management During General Anesthesia for Surgery — Completed
A Study of Elacytarabine (CP-4055) Plus Idarubicin as Second Course Remission-Induction Therapy in Patients With Acute Myeloid Leukaemia — Completed
Safety and Efficacy of Once-daily Oral Administrations of TZP-102 for Gastroparesis in Patients With Diabetes Mellitus — Completed
Safety and Efficacy of IV Infusion of Investigational Agent (TZP-101) in Patients With Severe Diabetic Gastroparesis — Completed
Strategies for Transfusion of Platelets (SToP) — Stopped early
Transfusion Medicine - Prevention of Bedside Errors — Completed